2024 GLP-1 RA products | Current Treatment: Physician Insights | US

Glucagon-like peptide-1 (GLP-1) receptor agonists, like SC semaglutide and liraglutide, and the glucose-dependent insulinotropic polypeptide (GIP) / GLP-1 receptor agonist tirzepatide have gained popularity in recent years owing to their impressive weight loss benefits. Additionally, these therapies are associated with robust glucose-level reductions and offer once-weekly and oral formulations. Because of these benefits, the GLP-1 and GIP / GLP-1 receptor agonists present an opportunity to address the intertwined challenges of treating type 2 diabetes (T2D) and obesity / overweight conditions. This content delves deep into the drivers of the GLP-1 and GIP / GLP-1 receptor agonist market, examining their usage and physicians’ perspectives.

Questions answered

• What is the perception of endocrinologists versus primary care physicians regarding the use of GLP-1 and GIP / GLP-1 receptor agonists for the treatment of T2D and obesity / overweight conditions?
• How have treatment practices evolved with the emergence of the GLP-1 and GIP / GLP-1 receptor agonists?
• What factors influence the prescription choices of endocrinologists when prescribing a GLP-1 and GIP / GLP-1 receptor agonist to their T2D patients who are also obese / overweight?
• When prescribing semaglutide to patients with T2D who are also obese / overweight, which brand (Ozempic, Rybelsus, or Wegovy) is most commonly prescribed by specialists, and what are the reasons?

Content highlights

• Geography: United States
• Primary research: survey of 101 U.S. endocrinologists and primary care physicians / general practitioners
• Key drugs covered: Byetta, Ozempic, Saxenda, Trulicity, Wegovy, Zepbound
• Key insights provided:
  • Factors influencing disease management and treatment decisions
  • Drivers and constraints of drug selection
  • Physician-reported treatment practices and brand-specific patient shares
  • Physician insight on persistency and compliance
  • Physician-reported recent / anticipated changes in brand usage or treatment approach

Product description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.